WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2016054406) COMPOSITIONS AND METHODS FOR INHIBITING BMP
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2016/054406 International Application No.: PCT/US2015/053545
Publication Date: 07.04.2016 International Filing Date: 01.10.2015
IPC:
C07D 401/14 (2006.01) ,C07D 417/14 (2006.01) ,C07D 221/22 (2006.01) ,C07D 403/02 (2006.01) ,A61K 31/551 (2006.01) ,C07D 213/02 (2006.01) ,C07D 401/04 (2006.01) ,C07D 409/04 (2006.01) ,A61K 31/44 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
417
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/196
14
containing three or more hetero rings
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
221
Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/-C07D219/187
02
condensed with carbocyclic rings or ring systems
22
Bridged ring systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
02
containing two hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
55
having seven-membered rings, e.g. azelastine, pentylenetetrazole
551
having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
213
Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
02
having three double bonds between ring members or between ring members and non-ring members
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
401
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
409
Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02
containing two hetero rings
04
directly linked by a ring-member-to-ring- member bond
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
44
Non-condensed pyridines; Hydrogenated derivatives thereof
Applicants: YU, Paul, B.[US/US]; US (US)
CUNY, Gregory, D.[US/US]; US (US)
MOHEDAS, Agustin, H.[US/US]; US (US)
LEE, Arthur[US/US]; US (US)
THE BRIGHAM AND WOMEN'S HOSPITAL, INC.[US/US]; 75 Francis Street Boston, MA 02115, US
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES[US/US]; Office of Technology Transfer National Institute of Health 6011 Executive Blvd., Ste. 325 Msc 7660 Bethesda, MD 20892-766, US
UNIVERSITY OF HOUSTON SYSTEM[US/US]; 316 E. Cullen Building 4800 Calhoun Houston, TX 77204-6001, US
Inventors: YU, Paul, B.; US
CUNY, Gregory, D.; US
MOHEDAS, Agustin, H.; US
LEE, Arthur; US
Agent: HALSTEAD, David P.; US
Priority Data:
62/058,37701.10.2014US
Title (EN) COMPOSITIONS AND METHODS FOR INHIBITING BMP
(FR) COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE BMP
Abstract:
(EN) The present invention provides small molecule inhibitors of BMP signaling and compositions and methods for inhibiting BMP signaling. These compounds and compositions may be used to modulate ceil growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascujar disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds and compositions may also be used to reduce circulating levels of ApoB- i 00 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.
(FR) La présente invention concerne des inhibiteurs à petites molécules de la signalisation BMP, et des compositions et des méthodes d'inhibition de la signalisation BMP. Ces composés et ces compositions peuvent être utilisés pour moduler la croissance, la différenciation, la prolifération et l'apoptose des cellules et ainsi être utiles pour le traitement de maladies ou d'états associés à la signalisation BMP, tels qu'une inflammation, une maladie cardiovasculaire, une maladie hématologique, un cancer et des troubles osseux, ainsi que pour moduler la différenciation et/ou la prolifération cellulaires. Ces composés et ces compositions peuvent également être utilisés pour réduire les taux circulants d'ApoB-i 00 ou de LDL et pour traiter ou prévenir les affections suivantes : l'hypercholestérolémie ou l'hyperlipoprotéinémie acquise ou congénitale ; les maladies, troubles ou syndromes associés à des défauts de l'absorption ou du métabolisme lipidique; ou les maladies, troubles ou syndromes provoqués par l'hyperlipidémie.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)